Contact | Print version | PDF version | Send article | RSS feed

Medicago signs MOU with Ajanta Pharma for commercial development of influenza vaccines in India and other territories

25 Aug 2009 - Medicago Inc. announced that it has signed a Memorandum of Understanding ("MOU") with Ajanta Pharma Limited to discuss and negotiate an agreement to commercialize Medicago's pandemic and seasonal influenza VLP-based vaccines in India and other territories. Under the terms of the MOU, the parties will evaluate and select an optimal deal structure with the objective of formalizing a definitive agreement within 90 days.
 
"This potential partnership with Ajanta will provide Medicago with another near-term commercial opportunity to broaden the deployment of our novel pandemic and seasonal influenza VLP vaccines and continue to validate our proprietary plant-based technologies," said Frederic Ors, VP Business Development of Medicago. "We intend to continue to pursue business opportunities of this nature and expand our footprint in regions that lack influenza vaccine manufacturing capabilities."